Splenic marginal zone lymphoma (SMZL) is a B-cell neoplasm whose molecular pathogenesis remains fundamentally unexplained, requiring more precise diagnostic markers. Previous molecular studies have revealed 7q loss and mutations of nuclear factor kB (NF-kB), B-cell receptor (BCR) and Notch signalling genes. We performed whole-exome sequencing in a series of SMZL cases. Results confirmed that SMZL is an entity distinct from other low-grade B-cell lymphomas, and identified mutations in multiple genes involved in marginal zone development, and others involved in NF-kB, BCR, chromatin remodelling and the cytoskeleton. Keywords: whole-exome sequencing; splenic; lymphoma; marginal zone INTRODUCTION Splenic marginal zone lymphoma (SMZL) is a relatively infrequent low-grade B-cell neoplasm that accounts for fewer than 2% of B-cell lymphomas. Description and recognition of SMZL is still quite dependent on the presence of histological features of marginal zone differentiation, as observed in the studies of spleen histology. This finding is acknowledged in the name of the entity, SMZL, as proposed by Schmidt and Isaacson.
INTRODUCTION
Splenic marginal zone lymphoma (SMZL) is a relatively infrequent low-grade B-cell neoplasm that accounts for fewer than 2% of B-cell lymphomas. Description and recognition of SMZL is still quite dependent on the presence of histological features of marginal zone differentiation, as observed in the studies of spleen histology. This finding is acknowledged in the name of the entity, SMZL, as proposed by Schmidt and Isaacson. 1 Recognizing the disorder is important, as patients with the condition have specific staging and are treated by specific therapeutic approaches. 2 Its differences from other B-cell lymphomas (chronic lymphocytic leukaemia, follicular lymphoma, mantle cell lymphoma, splenic red pulp lymphoma) may require the study of spleen histology in some cases. SMZL therapy is still essentially based on immunochemotherapy, and our limited knowledge of its molecular pathogenesis means that we are still far from being able to provide clinical applications in diagnosis or therapy.
Cytogenetic and copy number analysis have identified some recurrent alterations, such as 7q22-36 deletions (45-50%) and 3q gains (20-30%) . This has prompted the study of multiple potentially interesting genes located in these areas. 3, 4 The results of gene expression profiling have revealed a molecular signature of SMZL based on nuclear factor kB (NF-kB) activation and increased signalling from B-cell receptor (BCR) and tumour necrosis factor, together with other genes such as AKT, AP1, NOTCH2 and TCL1.
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A next-generation sequencing strategy has recently been used to explore the genome and exome of a series of SMZL patients, revealing recurrent mutations in NOTCH2 and in genes implicated in BCR and NF-kB signalling. 6, 7 Using whole-exome sequencing (WES) of a series of SMZL samples, we have identified mutations in genes involved in pathways that are key players in marginal zone differentiation and other essential functions of the cell.
MATERIALS AND METHODS

Patients and samples
A series of 15 initially diagnosed SMZL samples were selected for WES. Ten of the tumour samples corresponded to isolated CD19 cells from peripheral blood, whereas the other six corresponded to freshly frozen biopsies. For each case, matched control DNA was extracted from oral mucosae (13 cases), or from granulocytes when oral mucosa was not available (2 cases).
An extended series of 16 formalin-fixed paraffin embedded samples was used to sequence Notch2 exon 34 by Sanger sequencing.
Tumour cell purity of isolated cells (492%) and total frozen and formalin-fixed paraffin embedded biopsies (30-50%) were measured by fluorescence-activated cell sorting analysis, and hematoxylin and eosin/ CD20 staining, respectively. All cases were reviewed by a panel of three haematopathologists in accordance with current World Health Organization criteria. 8 Supplementary Table 6 shows the clinical data of the patients. All samples were from initial diagnostic specimens, taken before the patient received therapy. The project was approved by the ethics committee of Cantabria.
DNA extraction and quantification DNA was extracted by the phenol-chloroform method and the quantity and integrity of purified DNA was assessed by fluorometry (Qubit, Invitrogen, Life Technologies, Carlsbad, CA, USA) and 1% agarose gel electrophoresis.
Whole-exome enrichment and sequencing Whole-exome capture and sequencing were performed at the Spanish National Centre for Genomic Analysis (CNAG, Barcelona, Spain). Tumour and germline DNA were enriched in exome sequences using the SureSelect-XT Human exon capture 50Mb kit (Agilent Technologies, Santa Clara, CA, USA), according to the manufacturer's protocol. Paired-end 76-bp WES was performed using the Illumina HiSeq2000 instrument (Illumina, San Diego, CA, USA).
The sequence data have been deposited in the Sequence Read Archive at http://www.ncbi.nlm.nih.gov/sra/, with the accession number SRP033125.
Sequence mapping and identification of tumour variants
Base calling and quality control were performed on the Illumina RTA sequence analysis pipeline (Illumina). Sequence reads were trimmed until the first base was achieved with a quality of more than 10. Mapping to human genome build hg19 (GRCh37) was done with the Genome Multitool, allowing up to four mismatches. 9 Reads not mapped by Genome Multitool (approximately 4% of them) were submitted to a final round of mapping with BFAST. 10 Results were merged and only uniquely mapping non-duplicate read pairs were used for further analyses.
The SAMtools suite 11 with default settings was used to call single nucleotide variations and short insertions and deletions. Identified variants in regions with low mappability, 12 a read depth of o10 or a strand bias P-value o0.001 were filtered out. Variant annotation and effect prediction were performed with Annovar 13 and snpEff, 14 including information from the Single Nucleotide Polymorphism Database build 135, 15 the 1000 Genomes Project, 16 the Exome Variant Server (NHLBI GO Exome Sequencing Project, Seattle, WA, USA; http://evs.gs.washington. edu/EVS/) and an internal database of sequence variants identified in a set of more than 100 control samples. Tags were added for positions with high strand bias, high tail distance bias, read deptho10 and in low mappability regions. For tumour-normal comparison, the significance of Fisher's exact test was calculated for positions with different genotypes in the two samples.
Detection of subclonal mutations
To identify mutations present in subclonal populations inside the tumours, we used a slightly different analysis pipeline. Sequence reads were aligned to the human reference genome (GRCh37) using BWA, and the alignment was consequently cleaned using SAMtools and Picard tools for mating coordinate fixing and PCR duplicate flagging. Finally, GATK indel realigner (www.broadinstitute.org/gatk) was used to realign locally around small insertion and deletions (indels). A programme specifically written in-house named RAMSES ('Realignment Assisted Minimum Evidence Spotter', Ignacio Varela, manuscript in preparation) was used to identify coordinates with a minimum value of two independently aligned with BLAT, highquality reads reporting differences with the reference genome in the tumour sample and absolutely no evidence of the same change observed in the corresponding normal sample. In addition, mutations near DNA repeats, present in the Single Nucleotide Polymorphism Database and 1000 Genomes databases, or reported near the end of the reads were removed. The functional consequence of the mutations was annotated using the Ensembl perl API (Ensembl database, release 69) and only coding mutations were retained.
Validation of variants by 454 Roche
One hundred and forty-five candidate variants were subjected to validation by targeted resequencing using the GS Junior System (Roche, Basel, Switzerland). Approximately 300-bp amplicons around the identified mutations were generated, to which 454 specific adaptors were ligated. A pooled, barcoded mixture of amplicons was sequenced using a 454-Junior platform (Roche) obtaining a 200 Â average coverage for each amplicon. The reads corresponding to each sample (according to the barcode) were aligned against the human reference genome (GRCh37) using the BWA-SW algorithm. SAMtools was subsequently used to generate bam and pileup files. These latter types of file were parsed using scripts written in house. Only those positions with a minimum coverage of 20 in both tumour and normal samples were considered. Those mutations with at least five independent mutant reads in the tumour sample, corresponding to a minimum of 1% of the reads at that position, but with no mutant reads in the normal sample, were considered as validated.
Validation of variants by DNA Sanger sequencing and NOTCH2 sequencing Some of the candidate variants were subjected to validation by conventional Sanger-based sequencing of PCR products obtained from tumour and paired normal genomic DNA using primers specific to the region to which the variant mapped. In addition, a recently published hotspot for mutations in NOTCH2 was analysed by Sanger sequencing. Primers were designed using the Primer Blast (http://www.ncbi.nlm.nih.gov) design tool, described in the Supplementary Table 1 .
High-density single-nucleotide polymorphism array analysis Genome-wide DNA profiles were obtained from high-molecular-weight genomic DNA using the HumanOmni5-Quad microarrays (Illumina) following the manufacturer's protocols. Microarrays were scanned using an Illumina HiScanSQ instrument. Copy number (R) and allelic imbalance (Theta) data were exported using Illumina GenomeStudio software. Probes with an inter-probe distance of less than 180 bp were discarded. Copy number values were log 2 -transformed and median-centred to zero for autosomes and both sex chromosomes. For normalization, 12 HapMap samples were used as the reference and were pre-processed in the same way. Raw copy numbers were normalized by linear regression of the 12 reference profiles against each profile and subtraction of their contribution. Genomic profiles were segmented with the 'Fast first-derivative segmentation' algorithm. 3 Profiles were considered as poor quality and excluded from further analyses if they showed severe over-segmentation or no aberrations at all, as evaluated by two independent investigators (IK, FB). Table 2 ). Somatic variants were identified using the SAMtools suite (CNAG). In addition, the RAMSES programme (Ignacio Varela, University of Cantabria) for calling potential mutations showing a minimum independent multi-aligner evidence enabled less frequent variants (up to 5%) to be identified. Supplementary Tables 4 and 5 show all the variants detected in the patients, as well as the method with which each was detected.
RESULTS
Identification of somatic variants by WES
The most common substitution was the G4T/C4A transition (38.24%). Variations were classified as silent (218), missense (514), nonsense (36) , essential splice (19) and microRNA (5), according to their potential functional effect. The Polyphen algorithm enabled most of the variations to be classified as benign (223), possibly damaging (97) or probably damaging(183), whereas the SIFT algorithm enabled variations to be classified as tolerated (190) or deleterious (308; Figure 1 and Supplementary Tables 4 and 5) .
After filtering, 569 variants that produced an amino-acid change were found. As shown in Supplementary Table 4 , 69 of them were detected using the variant calling method developed by CNAG, 434 using RAMSES and 66 were detected by both methods. Those variants that appeared in genes known to be relevant in SMZL pathogenesis or tumour development were selected for further validation. Thus, 145 selected mutations in 131 genes were validated using the GS Junior System (Roche). In some cases, Sanger sequencing was performed when the coverage of the sequence obtained from the GS Junior System was too low. Overall, 65 mutations were validated: 33 out of 40 (82.5%) variants detected with the method used by the CNAG were validated. On the other hand, 57 out of 133 (42.86%) variants detected with RAMSES were validated (Supplementary Tables 4 and 5 ). The number of mutations detected in each patient varied between 0 (P10, P15) and 10 (P2; Table 1 ). Only one gene harboured mutations in more than one patient, in different positions, MYD88, which has been found mutated in three patients.
All the variants found in our SMZL series are described in Supplementary Table 4 . The mutated genes are mainly implicated in marginal zone development, NF-kB, chromatin remodelling and cytoskeleton (Figure 1b) . Surprisingly, no mutation was found in NOTCH2, a key gene in SMZL that acts as a master regulator of marginal zone differentiation. 17, 18 Recognizing the importance of this gene, and given the previous observations in SMZL, in which NOTCH2 mutations have been described in 21-25% of the cases, 6, 7 we decided to study the mutational status of NOTCH2 in an independent series. Therefore, exon 34 of the gene was sequenced by Sanger in these samples and in a separate series of 16 SMZL formalin-fixed paraffin embedded samples (Table 2) . One recurrent mutation was found in two samples from the second series, indicating an incidence of 6.45%. This mutation (c.7198C4T), which produces a stop codon, was described by Rossi et al. in 13.80% of the samples analysed. 7 Copy number alterations DNA from three patients was available for copy number variation analysis. The data revealed no alterations in the regions containing the genes harbouring the mutations, with the exception of TP53 in one patient, which featured mutation and genomic loss. Copy number alterations have been detected in regions harbouring the genes implicated in marginal zone regulation, such as gain of NOTCH1 and ARID3A, or loss of ARID4A. These data confirm the relevance of marginal zone regulation in the development of SMZL (Supplementary Table 3 ).
DISCUSSION
Our current knowledge about the genetic basis of SMZL development is incomplete and cannot explain the origin and development of this lymphoma or provide a basis for targeted therapy. Diagnostic markers are also needed to enable us to distinguish between SMZL and other B-cell lymphomas whose clinical presentation or morphology may overlap with those of SMZL, such as chronic lymphocytic leukaemia, prolymphocytic leaukaemia, nodal marginal zone lymphoma and other unclassified splenic B-cell lymphomas. Deep sequencing offers the opportunity to detect the structural changes and somatic mutations affecting genes or pathways that have a key role in the origin and development of SMZL. So far only two publications have described genetic alterations in SMZL revealed by nextgeneration sequencing technology. They show recurrent mutations in NOTCH2 and other genes that have a role in the marginal zone regulation. 6, 7 Here we have sequenced the exome of 15 SMZL samples and their normal counterparts, obtaining 569 variants that produce amino-acid change; 65 of these variants were validated. Surprisingly, no recurrent mutation has been found by WES of these cases. Figure 1 recapitulates the pathways known to be deregulated in SMZL, and identifies the mutated genes identified here and in previous studies. Four principal cellular processes have been found here altered by point mutations: marginal zone development, NF-kB pathway, chromatin remodelling and cytoskeleton.
Marginal zone development Marginal zone development arises as the most relevant pathway altered by point mutations in SMZL, together with NF-kB pathway. Almost half of the patients studied (7/15) had mutations in genes that are known to have a role in marginal zone development (Figure 1b) . For instance, ARID3A, also known as BRIGHT, which acts as a transcription factor associated with chromatin remodelling, [19] [20] [21] and encodes a member of the ARID (AT-rich interaction domain) family of DNA-binding proteins expressed at low levels in marginal zone B cells. [22] [23] [24] Recently, Oldham et al. demonstrated that BRIGHT transgenic mice exhibit defects in B-cell maturation and that constitutive Bright expression predisposes B cells to the development of marginal zone differentiation. 25 BTK, which was found to be mutated in one patient here, has a crucial role in B-cell development, marginal zone differentiation and signalling through the BCR/Bruton's tyrosine kinase (BTK) pathway. 26 Interestingly, BTK associates with ARID3A to bind DNA. 23 CXCR4, which is also involved in marginal zone development, harboured a truncating CXCR4 mutation in one sample studied here. This chemokine receptor has an important role in regulating homeostasis of B-cell compartments and humoral immunity. Indeed, it has been shown that in the absence of CXCR4, B-cell precursors are dislocated from bone marrow to peripheral blood and the spleen. 27 FAS also has a determinant role in maintaining the marginal zone 28 interaction with BTK and NF-kB, and in regulating the activation of the NF-kB and MAPK/ERK/JNK pathways.
The SPEN gene, a negative regulator of NOTCH2 that functions by binding to HDAC1 and blocking the differentiation of precursor B cells into marginal zone cells, 18 was found to be truncated by a somatic nonsense mutation in one of the patients. Truncating mutations were also found in 5% of SMZL patients by Rossi et al. using Sanger sequencing.
Our series of SMZL featured one recurrent mutation in NOTCH2 in 6.45% (2/31) of patients, in the same stop codon (R2400*) as described by Rossi et al. in 13.80% of their samples, and by Kiel et al. in 9.10% of their samples. This truncating mutation eliminates the PEST domain, which is required for proteasomal degradation of NOTCH2, and subsequent stabilization of the protein and increased activity. 7, 29 Our series had a relatively low proportion of cases (6.45%) with NOTCH2 mutations in the PEST domain, probably due to the small size of the series studied, and/or the tumour cell purity of the formalin-fixed paraffin embedded samples. Nevertheless, other genes involved in marginal zone differentiation were mutated in half (7/15) of the studied samples.
NF-kB pathway
The NF-kB pathway constitutes a key pathway in lymphoma development, promoting cell survival and differentiation in Abbreviations: NGS, next-generation sequencing; SNV, single nucleotide variation. P1-P15 corresponds to the samples analyzed by NGS and Sanger; P17-P32 corresponds to the samples analyzed only by Sanger. *DNA extracted from frozen tissue.
Whole-exome sequencing of splenic marginal zone lymphoma N Martínez et al normal B lymphocytes, and is constitutively activated in different types of lymphomas. This occurs by diverse mechanisms in response to increased signalling from BCR or TLR, as a consequence of somatic mutations in NF-kB genes. Importantly, nine of the patients analysed here harboured mutations in various activator genes of the NF-kB pathway. A notable one is the MYD88 L265P mutation, which was found in one case in this study. MYD88 is an adapter protein involved in Toll-like receptor signalling, leading to activation of the NF-kB pathway. L265P mutations have been described in a range of lymphoid neoplasms, especially IgM lymphoplasmacytic lymphoma, but it has also been observed in sporadic chronic lymphocytic leukaemia and SMZL cases. 7, 30 The case here found carrying on this change (MYD88 L265P, Case P2) lacked morphological signs of plasmacytic differentiation or presence of serum paraprotein, features usually found in the prolymphocytic leaukaemia associated with MYD88 L265P mutation.
Interestingly, some of the genes mutated in our samples have dual roles in the NF-kB pathway, BCR signalling, marginal zone development and/or chromatin remodelling, which confirms that these processes are critical to SMZL development, as is the case of ARID3A, CREBBP and FAS. One of the most remarkable mutated genes is ARID3A, which binds to DNA and is activated by p53 after DNA damage. ARID3A also binds to BTK, a key component of the BCR that was also found to be mutated in one sample, and to other DNA repair genes such as E2F1 and PML.
As we and other workers have shown, the gene expression and microRNA signatures of SMZL contain genes and microRNAs involved in NF-kB and B-cell receptor signalling pathways, which are some of the most important pathways involved in SMZL pathogenesis. 5, 31 The latest results of exome sequencing confirm the relevance of these pathways.
Chromatin organization
The chromatin organization is also highly altered in our patients. We found eight patients who harboured somatic mutations in at least one gene implicated in chromatin remodelling (Table 1) . Four members of histone cluster 1 (HIST1H1D, HIST1H1E, HIST1H2BI and HIST1H4H), which acts as a linker between nucleosomes, harboured mutations in four patients. Furthermore, SMARCA2, which encodes the catalytic unit of SWI/SNF ATP-dependent chromatin remodelling complex, was mutated in one patient. Alterations of the SWI/SNF pathway in different types of cancer, in which SMARCA2 is lost by various mechanisms, have been observed on several occasions. It seems that the loss of expression is driven by epigenetic mechanisms and that restoration of SMARCA2 (BRM) in deficient cells induces growth arrest. 32, 33 CHD2 was also found mutated in our study. This protein is important in development, haematopoiesis and tumour suppression. Moreover, CHD2 heterozygous mutant mice exhibit increased extramedullary haematopoiesis and a higher risk of lymphoma development. CHD2 mutant mice also show defective cellular differentiation and aberrant DNA damage responses. 34 Two patients harboured truncating mutations in BCOR and CREBBP. The latter protein is a histone acetyltransferase involved in the transcriptional coactivation of many different transcription factors. P53 and NF-kB have been shown to physically interact with CREB-binding protein and to require such an interaction to maximize their activities. 35 Thus, nuclear I-k-B kinase-a increases CREB-binding protein activity by phosphorylating CREB-binding protein at Ser-1382 and Ser-1386. 35 The truncative mutation found in one SMZL patient eliminates this position, as the protein is truncated at amino acid 1082. CREBBP is known to be mutated in several tumour types, including lymphoid neoplasms, such as diffuse large B-cell lymphoma, acute lymphoblastic leukaemia, acute myeloid leukaemia, follicular lymphoma and Burkitt lymphoma. [36] [37] [38] [39] The BCL6 corepressor protein BCOR is truncated by nonsense mutations in chronic myeloid leukaemia and acute myeloid leukaemia. 40 Here we have found a nonsense mutation that truncates the protein at amino acid 263. The truncated protein loses the BCL6-binding domain that comprises amino acids 498-514. 41 
Cytoskeleton
The cytoskeleton organization is the fourth cell process that was found to be notably altered in our SMZL series. Thus, seven patients each harboured a mutation in a gene that takes part in the remodelling of the cytoskeleton of the cell. ARHGAP25 and ARHGAP32 belong to Rho GTPase-activating proteins (ARHGAPs). These negatively regulate the Rho GTPases, which have a key role in regulating actin cytoskeleton organization in response to extracellular growth factors. SEMA3A is a member of the semaphorins, a family of more than 20 proteins that were first associated with axon guidance during development, but that are implicated in various processes, including tumorigenesis and metastasis. 42, 43 SEMA3A is involved in immune cell migration, and PLEXINA2, a member of the receptors of semaphorins, was found to be mutated in one case in our series.
Other truncating mutations Mutations that produce stop codons and consequently the synthesis of a truncated protein have been found in several genes.
APAF-1 is involved in apoptosis. It has a caspase recruitment domain, followed by a nucleotide-binding adaptor (NB-ARC domain), which is an ATPase domain, needed for the activation of the apoptosome. A truncating mutation was found in this domain, which probably produces an inactive protein.
FAT1 is a tumour suppressor, and a member of the cadherin superfamily. It is probably involved in YAP1 signalling, 44, 45 although this role remains controversial, as it has very recently been shown that, when inactivated, FAT1 leads to aberrant Wnt/bcatenin signalling in a range of cancer types. 46 This mutation is located in the cadherin domain of the protein.
MYCBP2, also known as PALM, functions as an E3 ubiquitin ligase and regulates TSC/mTOR signalling. 47 Loss of MYCBP2 constitutively activated p38 MAPK in peripheral sensory neurons in mice. 48 The data obtained here by next-generation sequencing and copy number variation strongly indicate that marginal zone regulation is the key process in SMZL development. The pathways and genes implicated in this process seem to be altered by mutation and/or deregulation of their expression. The findings confirm that SMZL is a distinctive clinicopathological and molecular entity, and provide knowledge that could enable a differential diagnosis from other B-cell lymphomas or lead to targeted therapy, as in the case of gamma-secretase-interfering NOTCH2 activity 49 or BTK inhibitors.
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